A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Phase Id/IIa Study Evaluating the Safety, Tolerability, and Pharmacokinetics of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM)
Latest Information Update: 28 Jul 2025
At a glance
- Drugs ZT 002 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors QL Biopharmaceutical
Most Recent Events
- 28 Jul 2025 New trial record